Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LCTX 
Lineage Cell Therapeutics Inc (LCTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: LCTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $3.92
1 Year Target Price $3.92
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.83% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 213.56M USD | Price to earnings Ratio - | 1Y Target Price 3.92 |
Price to earnings Ratio - | 1Y Target Price 3.92 | ||
Volume (30-day avg) 7 | Beta 1.52 | 52 Weeks Range 0.37 - 1.15 | Updated Date 06/30/2025 |
52 Weeks Range 0.37 - 1.15 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -169.57% | Operating Margin (TTM) -433.09% |
Management Effectiveness
Return on Assets (TTM) -12.1% | Return on Equity (TTM) -21.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 167897802 | Price to Sales(TTM) 22.35 |
Enterprise Value 167897802 | Price to Sales(TTM) 22.35 | ||
Enterprise Value to Revenue 17.57 | Enterprise Value to EBITDA -8.84 | Shares Outstanding 228356000 | Shares Floating 177741118 |
Shares Outstanding 228356000 | Shares Floating 177741118 | ||
Percent Insiders 0.42 | Percent Institutions 47.94 |
Analyst Ratings
Rating 3 | Target Price 3.92 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lineage Cell Therapeutics Inc
Company Overview
History and Background
Lineage Cell Therapeutics, Inc. was founded in 1990, initially focusing on a broad range of regenerative medicine technologies. Over time, the company narrowed its focus to cell therapies for degenerative diseases.
Core Business Areas
- Opal: This program is an allogeneic cell therapy in Phase 2a clinical development for spinal cord injury. It aims to restore motor and sensory function by creating new synapses at the injury site.
- OpRegen: This program is a retinal pigment epithelium (RPE) cell replacement therapy in Phase 2b clinical development for dry age-related macular degeneration (AMD) with geographic atrophy (GA). OpRegen is designed to replace cells lost to AMD, slowing or reversing vision loss.
- VAC2: VAC2 is an allogeneic cancer immunotherapy in Phase 1/2a clinical development for non-small cell lung cancer (NSCLC). VAC2 consists of antigen-presenting cells that are engineered to stimulate the patientu2019s immune system to recognize and kill cancer cells.
Leadership and Structure
Brian M. Culley is the CEO. The company has a board of directors and operates with a standard functional organizational structure, with departments for research and development, clinical trials, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- Opal: Opal is in Phase 2a clinical trials for spinal cord injury. Market share data is not yet available as the product is not yet commercialized. Competitors include companies developing other spinal cord injury therapies, such as pharmacological interventions, neuromodulation devices and stem cell treatments.
- OpRegen: OpRegen is in Phase 2b clinical trials for dry AMD with GA. Market share data is not yet available as the product is not yet commercialized. Competitors include Apellis (APLS) with Syfovre and Iveric Bio (ISEE), which was acquired by Astellas.
- VAC2: VAC2 is in Phase 1/2a clinical development for NSCLC. Market share data is not yet available as the product is not yet commercialized. Competitors include pharmaceutical companies developing cancer immunotherapies, such as Merck (MRK) with Keytruda and Bristol Myers Squibb (BMY) with Opdivo.
Market Dynamics
Industry Overview
The regenerative medicine industry is growing, driven by advances in cell therapy and gene therapy. There is significant unmet need for treatments for degenerative diseases like AMD and spinal cord injury.
Positioning
Lineage Cell Therapeutics is positioned as a cell therapy company focused on developing allogeneic cell therapies for unmet medical needs. Its competitive advantage lies in its intellectual property and manufacturing expertise in cell therapies.
Total Addressable Market (TAM)
The total addressable market for cell therapies targeting AMD and spinal cord injury is estimated to be in the billions of dollars. Lineage is positioned to capture a portion of this market if its therapies are approved.
Upturn SWOT Analysis
Strengths
- Proprietary cell therapy technology platform
- Advanced clinical development programs
- Experienced management team
- Strong intellectual property portfolio
- Allogeneic approach offers scalability.
Weaknesses
- Clinical trial risk
- Regulatory hurdles
- Need for significant capital investment
- Reliance on successful clinical outcomes
- Competition from established pharmaceutical companies
Opportunities
- Positive clinical trial results
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in cell therapy manufacturing
- Orphan drug designations
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other cell therapy companies
- Changes in healthcare reimbursement policies
- Economic downturn
Competitors and Market Share
Key Competitors
- APLS
- BMY
- MRK
- ISEE
Competitive Landscape
Lineage Cell Therapeutics faces competition from both large pharmaceutical companies and smaller biotechnology companies. Its competitive advantage lies in its proprietary cell therapy technology platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by advancements in clinical development programs and strategic partnerships.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals. Analyst estimates vary widely, reflecting the uncertainty inherent in the biotechnology industry.
Recent Initiatives: Recent initiatives include advancing OpRegen and Opal through clinical trials and expanding partnerships.
Summary
Lineage Cell Therapeutics is a clinical-stage biotechnology company with promising cell therapy programs targeting unmet medical needs. The success of the company hinges on positive clinical trial results and regulatory approvals. However, the company faces significant challenges, including clinical trial risk, regulatory hurdles, and competition. They have a strong proprietary cell therapy technology platform and an experienced management team, setting them up for potential success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports
- Company Website
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lineage Cell Therapeutics Inc
Exchange NYSE MKT | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 1992-03-06 | CEO, President & Director Mr. Brian M. Culley M.A., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://www.lineagecell.com |
Full time employees 70 | Website https://www.lineagecell.com | ||
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.